Centauri Therapeutics attended ID Week 2022
Jennifer Schneider, CEO and Helen Bright, VP of Research & Development at Centauri Therapeutics, attended ID Week 2022, which took place from 19th to 23rd October in Washington DC.
Helen presented an update on ABX01, our lead immune therapy programme targeting Gram-negative infections, during the “New Antimicrobials and ID Diagnostics in the Pipeline” session on Thursday morning.
ID Week is a premier infectious diseases event, which debuts research and connects colleagues from all around the world. The event comprises of lectures, symposia and workshops and aims to give attendees experience of cutting-edge advances in ID and to provide networking and professional development opportunities for ID professionals at all career stages.